欧洲 G-CSF/PEG-G-CSF 市场 – 行业趋势和 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

欧洲 G-CSF/PEG-G-CSF 市场 – 行业趋势和 2030 年预测

  • Healthcare
  • Published Report
  • Dec 2022
  • Europe
  • 350 页面
  • 桌子數: 99
  • 图号: 43

Europe G Csf Peg G Csf Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2024 –2030
Diagram Market Size (Base Year)
USD MILLION
Diagram Market Size (Forecast Year)
USD 1,692.13
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>欧洲 G-CSF/PEG-G-CSF 市场,按适应症(中性粒细胞减少症、肿瘤学、慢性和自身免疫性疾病、血液病、生长和谐缺陷等)、剂量(单一和组合)、给药途径(静脉注射、皮下注射)、包装(一次性小瓶和预填充注射器)、最终用户(医院和诊所、研究和学术机构、门诊手术中心等)、分销渠道(医院药房、网上药房、零售药房等)划分 - 行业趋势和预测到 2030 年。

欧洲 G-CSF/ PEG-G-CSF 市场

欧洲 G-CSF/ PEG-G-CSF 市场分析和见解

发达国家和政府对癌症预防的重视程度不断提高,并采取了有意识的举措来教育早期治疗,从而促进了欧洲生物仿制药 G-CSF 的销售市场。Grafeel、Colstim、Neukine 和 Filcad 是已获批准的生物仿制药,而且在发展中国家也具有成本效益且容易获得,将带来显著的市场增长。中国和印度是癌症患者数量不断增加的国家,这可能会提振欧洲市场。因此,与使用原始生物制剂相比,使用生物仿制药有助于降低患者的医疗保健成本,从而增加了欧洲 G-CSF 生物仿制药销售市场的需求。由于单个生物仿制药的生物制造过程复杂,生物仿制药的成本并不像仿制药那么低。自身免疫和罕见慢性疾病的日益流行预计将推动该细分市场的增长。

欧洲 G-CSF/ PEG-G-CSF 市场

欧洲 G-CSF/ PEG-G-CSF 市场

Data Bridge Market Research 分析,欧洲 G-CSF/PEG-G-CSF 市场预计到 2030 年将达到 16.9213 亿美元,预测期内复合年增长率为 5.1%。本市场报告还深入介绍了定价分析、专利分析和技术进步。

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021 (可定制至 2020-2015)

定量单位

收入(百万美元),定价(美元)

涵盖的领域

按适应症(中性粒细胞减少症、肿瘤学、慢性和自身免疫性疾病、血液病、生长协调性缺陷等)、剂量(单药和联合用药)、给药途径(静脉注射、皮下注射)、包装(一次性使用小瓶和预填充注射器)、最终用户(医院和诊所、研究和学术机构、门诊手术中心等)、分销渠道(医院药房、网上药房、零售药房等)

覆盖国家

德国、英国、法国、意大利、俄罗斯、荷兰、西班牙、瑞典、波兰、比利时、瑞士、丹麦、挪威、芬兰、土耳其、欧洲其他地区

涵盖的市场参与者

USV Private Limited、Viatris Inc.、Biocon、Fresenius Kabi AG、杭州九源基因工程有限公司、Amgen Inc.、Pfizer Inc.、Sandoz International GmbH、Apotex Inc.、Cadila Pharmaceuticals、Dr. Reddy's Laboratories Ltd.、Amneal Pharmaceuticals LLC.、Coherus BioSciences、Accord Healthcare、NAPP PHARMACEUTICALS LIMITED.、Intas Pharmaceuticals Ltd.、Mundipharma International、Teva Pharmaceutical Industries Ltd.、Spectrum Pharmaceuticals, Inc.、Kyowa Kirin Co., Ltd.、江苏恒瑞制药股份有限公司等。

欧洲 G-CSF/ PEG-G-CSF 市场定义

粒细胞集落刺激因子 (G-CSF) 是一种用于治疗中性粒细胞减少症的药物。这是一种白细胞数量低于平均水平的疾病,是由某些形式的化疗引起的。G-CSF 的主要类型是来诺格司亭 (Granocyte)、非格司亭 (Neupogen、zarzio、nivestim、accofil)、长效 (聚乙二醇化) 非格司亭 (pegfilgrastim、neulasta、pelmeg、ziextenco) 和利培非格司亭 (lonquex)。来诺格司亭是一种糖基化重组治疗剂,其化学性质与天然存在的人类粒细胞集落刺激因子 (G-CSF) 相似或相同。各种产品包括片剂和胶囊,可治疗癌症、血液疾病、生长激素缺乏症以及慢性和自身免疫性疾病。

欧洲 G-CSF/ PEG-G-CSF 市场动态

本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容:    

驱动程序

  • 血癌和癌症发病率不断上升

癌症是多种疾病的总称,这些疾病会影响身体的任何部位。癌症的其他术语包括恶性肿瘤和肿瘤。癌症的特征之一是异常细胞的快速形成,这些细胞生长超出正常范围,可以侵入身体的邻近部位并扩散到其他器官;后一个过程称为转移。广泛转移是癌症死亡的主要原因。

非格司亭是一种粒细胞集落刺激因子 (GCSF),有助于增加血液中的中性粒细胞数量。非格司亭和聚乙二醇非格司亭被广泛用于在癌症化疗或放射治疗后增加白细胞。

因此,血癌和癌症病例的增加将在未来几年推动欧洲 G-CSF / PEG-G-CSF 市场的发展。

  • 发热性中性粒细胞减少症病例增加

发热性中性粒细胞减少症是指在严重中性粒细胞减少症期间发烧。如果患者患有中性粒细胞减少症,其感染风险可能高于平常,特定感染的严重程度也可能更高。发热性中性粒细胞减少症是癌症治疗中最常见的危及生命的并发症;其治疗通常是肿瘤急症。

发热性中性粒细胞减少症是伴有发烧的中性粒细胞减少症。中性粒细胞减少症是指血液中中性粒细胞浓度下降。中性粒细胞是一种白细胞,作为免疫系统的一部分,有助于抵抗感染。美国传染病协会将中性粒细胞减少症定义为绝对中性粒细胞计数 (ANC) 低于 1500 个细胞/立方毫米。重度中性粒细胞减少症的感染和中性粒细胞减少性发热风险急剧增加,重度中性粒细胞减少症的定义为绝对中性粒细胞计数 (ANC) 低于 500 个细胞/立方毫米。发烧定义为单次口腔温度大于或等于 101° 华氏度 (38.3° 摄氏度) 或持续体温大于或等于 100.4° 华氏度 (38.0° 摄氏度) 或更高,持续一小时或更长时间。

欧洲癌症研究与治疗组织、美国临床肿瘤学会、美国国家癌症网络三大国际癌症组织最新指南一致认为,对于化疗引起的发热性中性粒细胞减少症,应预防性给予非格司亭或培非格司亭。≥20%或风险为10-20%且患者存在其他发热性中性粒细胞减少症风险因素。

因此,发热性中性粒细胞减少症病例的增加将在未来几年进一步推动欧洲 G-CSF / PEG-G-CSF 市场的发展。

克制

  • 严格的政府法规

开发非格司亭等生物仿制药的制药公司在产品审批过程中面临着重大挑战。每个国家对所有药物、治疗、疫苗和医疗器械的审批流程都不同。然而,这些审批程序很难遵循。这是因为需要各种法规和证据来证明产品的有效性和安全性。

欧洲药品管理局的监管要求确保生物仿制药与原研生物制品具有相同的高质量、安全性和有效性标准。这些要求还包括与参考产品进行严格的可比性测试,但欧盟以外的监管机构并未普遍接受这些要求。值得注意的是,如果印度批准的“类似生物制剂”、伊朗批准的“生物仿制药”、阿根廷批准的“类似生物药物”和南非批准的非原研生物制品受到欧盟批准生物仿制药所需的严格监管程序,它们可能不会获得授权。

由于政府的严格监管,G-CSF/PEG-G-CSF 的生产和制造必须遵守各个监管机构的规定,这阻碍了欧洲 G-CSF/PEG-G-CSF 市场的增长。

机会

  • 使用生物仿制药有助于降低患者的医疗成本

生物仿制药有可能从根本上改变医疗保健,为患者提供更实惠、同样有效的治疗,并为医生提供更多治疗选择。开发生物仿制药需要进行严格的分析,以证明其与参考产品的等效性,并确保其安全性、有效性和纯度没有临床意义上的差异。因此,卫生系统可以将长期节省的资金用于患者护理的整体改善。为了帮助创造一个蓬勃发展的生物仿制药市场并确保患者能够获得药物,政策制定者可以采取措施降低或消除生物仿制药的成本,并鼓励医生开出与欧洲相比更好的生物仿制药。

生物仿制药有可能扩大治疗选择并提高医疗公平性。同时,它们还可以为个体患者和医疗系统节省资金。通过立法和宣传工作以及未来的举措,这些有效药物的可及性可以扩大,并从根本上改变需要这些药物的患者的健康服务。

因此,使用生物仿制药有助于降低患者的医疗成本。这一因素为市场增长创造了机会。

挑战

  • G-CSF 的多种副作用

粒细胞集落刺激因子 (G-CSF) 是一种用于治疗中性粒细胞减少症的药物,中性粒细胞减少症是一种疾病,某些形式的化疗会导致白细胞数量低于平均水平。G-CSF 是一种生长因子,可使骨髓产生更多的白细胞,以降低某些类型的癌症治疗后感染的风险。但是 G-CSF 有多种副作用,例如骨骼或肌肉疼痛、瘀伤、牙龈出血或流鼻血、腹泻、高烧(发烧)、呼吸困难和面色苍白、口腔、喉咙、肠道和肛门疼痛等。每 100 人中就有超过 10 人(超过 10%)会出现这些副作用。

根据 NCBI 的一项研究,大多数接受 G-CSF 的正常捐献者都会出现副作用,但程度都为轻度至中度。90% 的捐献者都经历过 G-CSF 的一些副作用。最常见的副作用是骨痛 (83%)、头痛 (39%)、身体疼痛 (23%)、疲劳 (14%) 以及恶心和呕吐 (12%),这预计将对市场增长构成挑战。

因此,G-CSF 的副作用日益增加,对市场增长构成了挑战。

新冠肺炎疫情对欧洲 G-CSF/ PEG-G-CSF 市场的影响

COVID-19 疫情对 G-CSF/PEG-G-CSF 市场产生了一定程度的积极影响。疫情实施了新的规范和法规,例如保持社交距离和封锁,以防止病毒传播。结果,世界各地的人们被迫待在家里,这导致了在家工作等新趋势的出现。这种居家生活导致疾病诊断和预后减少。在疫情之后,人们对自我护理、锻炼和健康的关注度增加,帮助健身应用和平台获得了显著的关注。

制造商正在制定各种战略决策,以在新冠疫情后实现复苏。参与者正在进行多项研发活动、产品发布和战略合作,以改进移植诊断市场所涉及的技术和测试结果。

最新动态

  • 2018 年 7 月,Intas Pharmaceuticals Ltd. 的子公司 Accord Healthcare 在获得 CHMP(人用药品委员会)批准 Pelgraz®(培非格司亭)后,在欧洲推出了培非格司亭生物仿制药。该产品的推出帮助该公司拓展了其在欧洲的业务。
  • 2022 年 3 月,Kashiv Biosciences 宣布其生物制品许可申请 (BLA) 已获美国食品药品监督管理局 (FDA) 批准,该药物为 filgrastim-ayow,这是一种参考 Neupogen 的生物仿制药。该产品以专有名称 RELEUKO 销售。

欧洲 G-CSF/ PEG-G-CSF 市场范围

欧洲 G-CSF/PEG-G-CSF 市场细分为适应症、剂量、给药途径、包装、最终用户和分销渠道。各细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。

欧洲 G-CSF / PEG-G-CSF 市场,按适应症划分

  • 中性粒细胞减少症
    • 化疗引起的发热性中性粒细胞减少症(骨髓抑制化疗治疗)
    • 严重慢性中性粒细胞减少症
    • 放射治疗引起的中性粒细胞减少症
    • HIV 患者的中性粒细胞减少症
    • 氯氮平诱发的中性粒细胞减少症
    • 丙型肝炎患者的中性粒细胞减少症
    • 先天性中性粒细胞减少症
  • 肿瘤学
    • 接受巩固化疗的急性髓系白血病
    • 其他的
  • 慢性和自身免疫性疾病
  • 血液疾病
  • 生长激素缺乏症
  • 其他的

根据适应症,欧洲 G-CSF/PEG-G-CSF 进一步细分为中性粒细胞减少症、肿瘤学、慢性和自身免疫性疾病、血液病、生长激素缺乏症等。

欧洲 G-CSF / PEG-G-CSF 市场,按剂量划分

  • 单核细胞增多症
  • 组合

根据剂量,欧洲 G-CSF/PEG-G-CSF 进一步分为单一剂量和组合剂量。

欧洲 G-CSF / PEG-G-CSF 市场,按给药途径划分

  • 静脉
  • 皮下

根据给药途径,欧洲G-CSF/PEG-G-CSF进一步分为静脉注射和皮下注射。

欧洲 G-CSF / PEG-G-CSF 市场,按包装分类

  • 一次性使用小瓶
  • 预充式注射器

根据包装,欧洲 G-CSF/PEG-G-CSF 进一步细分为一次性小瓶和预填充注射器。

欧洲 G-CSF / PEG-G-CSF 市场,按最终用户划分

  • 医院和诊所
  • 研究与学术机构
  • 门诊手术中心
  • 其他的

根据最终用户,欧洲 G-CSF/PEG-G-CSF 进一步细分为医院和诊所、研究和学术机构、门诊手术中心和其他。

欧洲 G-CSF / PEG-G-CSF 市场,按分销渠道划分

  • 医院药房
  • 网上药店
  • 零售药店
  • 其他的

根据分销渠道,欧洲 G-CSF/PEG-G-CSF 进一步细分为医院药房、网上药房、零售药房和其他。

G-CSF/ PEG-G-CSF 市场

欧洲 G-CSF/ PEG-G-CSF 市场区域分析/见解

对欧洲 G-CSF/PEG-G-CSF 市场进行分析,并根据国家、适应症、剂量、给药途径、包装、最终用户和分销渠道提供市场规模信息。

欧洲 G-CSF/PEG-G-CSF 市场包括德国、英国、法国、意大利、俄罗斯、荷兰、西班牙、瑞典、波兰、比利时、瑞士、丹麦、挪威、芬兰、土耳其和欧洲其他地区。

预计德国将凭借其在 G-CSF/PEG-G-CSF 领域的最新先进技术和发明而实现增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在对国家数据进行预测分析时,还考虑了欧洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战,以及销售渠道的影响。

竞争格局和欧洲 G-CSF/PEG-G-CSF 市场份额分析

欧洲 G-CSF/ PEG-G-CSF 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对欧洲 G-CSF/ PEG-G-CSF 市场的关注有关。

在该市场开展业务的一些主要公司包括 USV Private Limited、Viatris Inc.、Biocon、Fresenius Kabi AG、杭州九源基因工程有限公司、Amgen Inc.、Pfizer Inc.、Sandoz International GmbH、Apotex Inc.、Cadila Pharmaceuticals、Dr. Reddy's Laboratories Ltd.、Amneal Pharmaceuticals LLC.、Coherus BioSciences、Accord Healthcare、NAPP PHARMACEUTICALS LIMITED.、Intas Pharmaceuticals Ltd.、Mundipharma International、Teva Pharmaceutical Industries Ltd.、Spectrum Pharmaceuticals, Inc.、Kyowa Kirin Co., Ltd.、江苏恒瑞制药股份有限公司等。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE G-CSF / PEG-G-CSF MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 EUROPE G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION

4.4 EUROPE G-CSF / PEG-G-CSF MARKET

4.5 STRATEGIES TO THE ENTER THE MARKET

4.5.1 JOINT VENTURE (PARTNERSHIPS):

4.5.2 ACQUISITION:

4.5.3 LINE EXPANSION VIA COLLABORATION:

4.5.4 PRODUCT APPROVAL:

4.5.5 PRODUCT LAUNCH:

4.5.6 GEOGRAPHIC EXPANSION:

4.5.7 COST LEADERSHIP:

4.5.8 PRODUCT DEVELOPMENT:

4.6 EUROPE G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS

4.6.1 PATENT ANALYSIS

4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS

4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

4.6.4 THERAPEUTIC ASSESSMENT

4.6.5 KEY PRICING STRATEGIES

4.6.6 KEY PATIENT ENROLLMENT STRATEGIES

4.6.7 CONCLUSION

4.7 PIPELINE ANALYSIS FOR EUROPE G-CSF / PEG-G-CSF MARKET

5 EPIDEMIOLOGY

6 EUROPE G-CSF / PEG-G-CSF MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES

7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS

7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA

7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM

7.2 RESTRAIN

7.2.1 STRINGENT GOVERNMENTAL REGULATIONS

7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY

7.3 OPPORTUNITIES

7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS

7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS

7.4 CHALLENGES

7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY

7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF

8 EUROPE G-CSF/ PEG-G-CSF MARKET, BY INDICATION

8.1 OVERVIEW

8.2 NEUTROPENIA

8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT)

8.2.2 SEVERE CHRONIC NEUTROPENIA

8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA

8.2.4 NEUTROPENIA IN HIV PATIENTS

8.2.5 CLOZAPINE INDUCED NEUTROPENIA

8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS

8.2.7 CONGENITAL NEUTROPENIA

8.3 ONCOLOGY

8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY

8.3.2 OTHERS

8.4 CHRONIC AND AUTO IMMUNE DISEASES

8.5 BLOOD DISORDERS

8.6 GROWTH HORMONE DEFICIENCY

8.7 OTHERS

9 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DOSAGE

9.1 OVERVIEW

9.2 MONO

9.3 COMBINATION

10 EUROPE G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 SUBCUTANEOUS

10.3 INTRAVENOUS

11 EUROPE G-CSF/ PEG-G-CSF MARKET, BY PACKAGING

11.1 OVERVIEW

11.2 PRE FILLED SYRINGES

11.3 SINGLE USE VIALS

12 EUROPE G-CSF/ PEG-G-CSF MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS AND CLINICS

12.3 RESEARCH & ACADEMIC INSTITUTES

12.4 AMBULATORY SURGICAL CENTERS

12.5 OTHERS

13 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 HOSPITALS PHARMACY

13.3 RETAIL PHARMACY

13.4 ONLINE PHARMACY

13.5 OTHERS

14 EUROPE G-CSF/PEG-G-CSF MARKET, BY REGION

14.1 EUROPE

14.1.1 RUSSIA

14.1.2 TURKEY

15 EUROPE G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: EUROPE

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 PFIZER INC.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENTS

17.2 VIATRIS INC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 AMGEN INC.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENTS

17.4 STADA ARZENEIMITTEL AG

17.4.1 COMPANY SNAPSHOT

17.4.2 COMPANY SHARE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENT

17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENTS

17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENTS

17.7 ACCORD HEALTHCARE

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENTS

17.8 AMNEAL PHARMACEUTICALS LLC.

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENTS

17.9 APOTEX INC.

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 BIOCON

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 BIO SIDUS

17.11.1 COMPANY SNAPSHOT

17.11.2 PRODUCT PORTFOLIO

17.11.3 RECENT DEVELOPMENTS

17.12 CADILA PHARMACEUTICALS

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENTS

17.13 COHERUS BIOSCIENCES

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 DR. REDDY’S LABORATORIES LTD

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENTS

17.15 FRESENIUS KABI AG

17.15.1 COMPANY SNAPSHOT

17.15.2 PRODUCT PORTFOLIO

17.15.3 RECENT DEVELOPMENT

17.16 GENNOVA BIOPHARMACEUTICALS LIMITED

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENTS

17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD.

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENTS

17.18 INTAS PHARMACEUTICALS LTD.

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENT

17.19 KASHIV BIOSCIENCES, LLC.

17.19.1 COMPANY SNAPSHOT

17.19.2 PRODUCT PORTFOLIO

17.19.3 RECENT DEVELOPMENT

17.2 KYOWA KIRIN CO., LTD.

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENT

17.21 LUPIN

17.21.1 COMPANY SNAPSHOT

17.21.2 REVENUE ANALYSIS

17.21.3 PRODUCT PORTFOLIO

17.21.4 RECENT DEVELOPMENT

17.22 MUNDIPHARMA INTERNATIONAL.

17.22.1 COMPANY SNAPSHOT

17.22.2 PRODUCT PORTFOLIO

17.22.3 RECENT DEVELOPMENT

17.23 NAPP PHARMACEUTICALS LIMITED

17.23.1 COMPANY SNAPSHOT

17.23.2 PRODUCT PORTFOLIO

17.23.3 RECENT DEVELOPMENT

17.24 RELIANCE LIFE SCIENCES

17.24.1 COMPANY SNAPSHOT

17.24.2 PRODUCT PORTFOLIO

17.24.3 RECENT DEVELOPMENTS

17.25 SANDOZ INTERNATIONAL GMBH

17.25.1 COMPANY SNAPSHOT

17.25.2 REVENUE ANALYSIS

17.25.3 PRODUCT PORTFOLIO

17.25.4 RECENT DEVELOPMENTS

17.26 SPECTRUM PHARMACEUTICALS, INC.

17.26.1 COMPANY SNAPSHOT

17.26.2 PRODUCT PORTFOLIO

17.26.3 RECENT DEVELOPMENT

17.27 USV PRIVATE LIMITED

17.27.1 COMPANY SNAPSHOT

17.27.2 PRODUCT PORTFOLIO

17.27.3 RECENT DEVELOPMENTS

18 QUESTIONNAIRE

19 RELATED REPORTS

表格列表

TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET:

TABLE 2 EUROPE G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 3 EUROPE NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 EUROPE NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 5 EUROPE ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 EUROPE ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 7 EUROPE CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 EUROPE BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 EUROPE GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION)

TABLE 12 EUROPE MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION)

TABLE 18 EUROPE PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 21 EUROPE HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 26 EUROPE HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 EUROPE RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 EUROPE ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 EUROPE OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION)

TABLE 31 EUROPE G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION)

TABLE 32 EUROPE G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 33 EUROPE NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 34 EUROPE ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 35 EUROPE G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 36 EUROPE G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 37 EUROPE G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 38 EUROPE G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 39 EUROPE G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 40 RUSSIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 41 RUSSIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 42 RUSSIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 43 RUSSIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 44 RUSSIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 45 RUSSIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 46 RUSSIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 47 RUSSIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 48 RUSSIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 49 RUSSIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 50 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 51 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 52 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 53 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 54 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 55 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 56 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 57 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 58 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 59 RUSSIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 60 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 61 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 62 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 63 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 64 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 65 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 66 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 67 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 68 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 69 TURKEY G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 70 TURKEY NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 71 TURKEY ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 72 TURKEY G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 73 TURKEY MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 74 TURKEY G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 75 TURKEY SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 76 TURKEY INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 77 TURKEY G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 78 TURKEY PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 79 TURKEY SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 80 TURKEY G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 81 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 82 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 83 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 84 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 85 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 86 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 87 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 88 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 89 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 90 TURKEY G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 91 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 92 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 93 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 94 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 95 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 96 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 97 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 98 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 99 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

图片列表

FIGURE 1 EUROPE G-CSF / PEG-G-CSF MARKET: SEGMENTATION

FIGURE 2 EUROPE G-CSF / PEG-G-CSF MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE G-CSF / PEG-G-CSF MARKET: DROC ANALYSIS

FIGURE 4 EUROPE G-CSF / PEG-G-CSF MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE G-CSF / PEG-G-CSF MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE G-CSF / PEG-G-CSF MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE G-CSF / PEG-G-CSF MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE G-CSF / PEG-G-CSF MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EUROPE G-CSF / PEG-G-CSF MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE G-CSF / PEG-G-CSF MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN CANCER PROPHYLAXIS IN DEVELOPED COUNTRIES AND INITIATIVES TAKEN BY GOVERNMENTS ARE TO DRIVE THE EUROPE G-CSF / PEG-G-CSF MARKET FROM 2023 TO 2030

FIGURE 12 NEUTROPENIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE G-CSF / PEG-G-CSF MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE G-CSF / PEG-G-CSF MARKET

FIGURE 14 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2022

FIGURE 15 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2021-2030 (USD MILLION)

FIGURE 16 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, CAGR (2022-2029)

FIGURE 17 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, LIFELINE CURVE

FIGURE 18 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2022

FIGURE 19 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2021-2030 (USD MILLION)

FIGURE 20 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, CAGR (2023-2030)

FIGURE 21 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, LIFELINE CURVE

FIGURE 22 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 23 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

FIGURE 24 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 25 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2022

FIGURE 27 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2021-2030 (USD MILLION)

FIGURE 28 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, CAGR (2023-2030)

FIGURE 29 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 30 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, 2022

FIGURE 31 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, 2021-2030 (USD MILLION)

FIGURE 32 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

FIGURE 36 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 EUROPE G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022)

FIGURE 39 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022)

FIGURE 40 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)

FIGURE 41 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 EUROPE G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030)

FIGURE 43 EUROPE G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Europe G-CSF/PEG-G-CSF Market is projected to grow at a CAGR of 5.1% during the forecast period by 2030.
The future market value of the Europe G-CSF/PEG-G-CSF Market is expected to reach USD 1,692.13 million by 2030.
The major players in the Europe G-CSF/PEG-G-CSF Market are USV Private Limited, Viatris Inc., Biocon, Fresenius Kabi AG, Hangzhou Jiuyuan Gene Engineering Co., Ltd., Amgen Inc., Pfizer Inc., Sandoz International GmbH, Apotex Inc., Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., etc.
The countries covered in the Europe G-CSF/PEG-G-CSF Market are Germany, U.K., France, Italy, Russia, Netherlands, Spain, Sweden, Poland, Belgium, Switzerland, Denmark, Norway, Finland, Turkey, Rest of Europe.